Immuneering Corporation

NASDAQ•IMRX

CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

板块: Healthcare

行业: Biotechnology

上市日期: 2021-07-30

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

联系方式

245 Main Street, Second Floor, Cambridge, MA, 02142, United States

617-500-8080

immuneering.com

市值

$208.74M

市盈率 (TTM)

-4.5

股息率

52周最高

$10.08

52周最低

$1.10

52周范围

52%

排名44Top 53.8%

3.7

F-Score

改良版 Piotroski 分析

基于 6 年期基本面

疲弱 • 3.7 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2020-2025

财务仪表盘

Q4 2025 数据

营业收入

$0.00+0.00%

近4季度走势

每股收益

-$0.18+0.00%

近4季度走势

自由现金流

-$9.96M+0.00%

近4季度走势

2025 Annual 财报亮点

核心亮点

Net Loss Decreased Net loss $56.0M for 2025, an 8.2% reduction compared to $61.0M loss reported in 2024.

R&D Spending Reduced Total R&D expenses fell 12.3% to $42.0M in 2025, driven by pausing envometinib program development efforts.

Significant Capital Raised Financing activities provided $226.6M cash, reflecting multiple private placements and public equity offerings during 2025.

Cash Runway Extended Cash reserves $128.6M as of year-end, sufficient to fund operations and development activities into 2029.

关注风险

Late-Stage Clinical Dependency Business substantially dependent on successful atebimetinib development; no products approved for commercial sale currently.

Substantial Capital Needs Requires substantial additional capital to finance operations; failure to raise funds delays or eliminates development programs.

Regulatory Approval Unpredictable Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable regarding outcomes for candidates.

Platform Technology Reliance Business substantially dependent on proprietary platform and information technology systems; failure materially harms operations.

前瞻展望

Phase 3 Trial Dosing Planned Expect dosing first patient in atebimetinib Phase 3 MAPKeeper 301 trial in mid-2026 for pancreatic cancer indication.

Atebimetinib Data Updates Announce further updated survival data from over 50 first-line pancreatic cancer patients in first half of 2026.

New Combination Trial Dosing Dosing first patient in planned atebimetinib combination trial with Libtayo in NSCLC patients second half 2026.

Envometinib Partnership Focus Paused internal advancement of envometinib; pursuing partnership opportunities and considering other developmental paths.

同行对比

营业收入 (TTM)

ARCT

$74.12M

-46.4%

ASMB

$72.30M

+153.5%

CDXS

$70.39M

+18.6%

毛利率 (最新季度)

PYXS

103.9%

+0.0pp

ENTA

100.0%

+0.0pp

ASMB

99.9%

+0.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
SLS	$699.39M	-28.0	-63.1%	1.3%
TRDA	$535.60M	-4.0	-39.8%	13.5%
ASMB	$472.87M	-54.6	-5.6%	1.0%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

N/M

营收波动较大

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年5月4日

每股收益:-$0.30

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据